Naltrexone

Research Update

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

Topics: Addiction Treatment | Naltrexone | Opioid Use Disorder | Research Update

Review of: Sullivan MA et al, Am J Psychiatry 2017;174(5):459–467 Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone? While i

Read More
Research Update

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

Topics: Naltrexone | Opioids | Research Update

Review of: Latif Z et al, JAMA Psychiatry 2019;76(2):127–134 Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade

Read More
Research Update

Switching from Buprenorphine to Extended-Release Naltrexone: Does it Work?

Topics: Buprenorphine | Naltrexone | Opioids | Research Update | Substance Use

Review of: Solli KK et al, Addiction 2018;113(10):1840-1849 Extended-release naltrexone (Vivitrol) has had some good data, yet getting patients on it remains a challenge, because an opioid-free period is required before starting it. Understandably, practitioners get nervous when patients stabilized on buprenorphine ask to be transitioned to extended-

Read More